To investigate whether TIGIT expression in CD8+ TILs in human cancer is predictive to anti-TIGIT therapy could provide insights into a novel and inexpensive tool for patients’ treatment stratification, thus potentially reducing overtreatment and collateral effects. Here, CD8A is linked to cancer.